VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the topline results from its Phase 2b trial of Repibresib Gel for the treatment of nonsegmental vitiligo. The trial, conducted across 45 sites in North America, did not meet its primary endpoint of achieving F-VASI50 or the key secondary endpoint of F-VASI75 at Week 24. However, nominally statistically significant effects were observed in secondary and exploratory endpoints at a 3% concentration, indicating a reduction in the percent change from baseline in both F-VASI and T-VASI. Due to these results, the company plans to terminate the extension phase of the trial and seek an external partner for further development of Repibresib. VYNE intends to conduct a thorough evaluation of the full dataset to inform strategic next steps and will provide updates on future plans, including those for their oral BET inhibitor VYN202, in the coming weeks.